| 3GC | Third-generation cephalosporin |
| AC | Antimicrobial consumption |
| AMR | Antimicrobial resistance |
| AS | Antimicrobial stewardship |
| BSI | Bloodstream infection |
| CAESAR | Central Asian and European Surveillance of Antimicrobial Resistance |
| CDI | Clostridioides difficile infection |
| Cef R | Third-generation cephalosporin-resistant |
| Cef S | Third-generation cephalosporin-susceptible |
| CL | Change in level |
| COVID-19 | Coronavirus disease 2019 |
| CR | Carbapenem-resistant |
| CRAB | Carbapenem-resistant Acinetobacter baumanii |
| CR-GNB | Carbapenem-resistant Gram-negative bacteria |
| CRO | Carbapenem-resistant organism |
| CS | Carbapenem-susceptible |
| CT | Change in trend |
| DDD | Defined daily dose |
| EARS-Net | European Antimicrobial Resistance Surveillance Network |
| HAI | Healthcare-associated infection |
| ICU | Intensive care unit |
| ID | Incidence density |
| IPC | Infection prevention and control |
| MDROs | Multidrug-resistant organisms |
| MRSA | Methicillin-resistant Staphylococcus aureus |
| MSSA | Methicillin-susceptible Staphylococcus aureus |
| PAF | Prospective audit and feedback |
| PD | Patient-days |
| PPE | Personal protective equipment |
| SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 |
| VAP | Ventilator-associated pneumonia |
| VR | Vancomycin-resistant |
| VS | Vancomycin-susceptible |